Can I Take Resveratrol with CJC-1295?

What CJC-1295 (Modified GRF) Actually Does

CJC-1295 modified GRF is a synthetic, 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and drives pulsatile release of endogenous GH, which then stimulates hepatic IGF-1 production. The non-DAC (Drug Affinity Complex) form has a plasma half-life of roughly 30 minutes, while the DAC-conjugated version extends that to 6 to 8 days by binding serum albumin [1].

Mechanism at the pituitary

Activation of the GHRH receptor triggers cyclic AMP accumulation and protein kinase A signaling in somatotroph cells [2]. This is a G-protein-coupled pathway. Any compound that alters intracellular cAMP, steroid receptor signaling, or hepatic IGF-1 processing could, in theory, shift the net GH response.

Regulatory and compounding status

CJC-1295 carries no FDA-approved indication for human use. It is dispensed in the United States only through 503A compounding pharmacies under an individualized prescription [3]. The FDA has flagged several peptide compounds, including CJC-1295, as biologics that fall outside standard 503A compounding authority. Clinicians prescribing it should confirm their compounding pharmacy's current compliance status.

How Resveratrol Is Metabolized

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in red-grape skin, Japanese knotweed, and numerous supplement products. After oral ingestion, absorption reaches 70 to 75%, but first-pass glucuronidation and sulfation reduce bioavailability to roughly 1% for the unchanged aglycone [4]. Peak plasma concentrations after a 250 mg oral dose average around 491 ng/mL before rapid conjugation [5].

CYP enzyme inhibition

Resveratrol inhibits CYP1A1, CYP1B1, CYP3A4, and CYP2E1 in human liver microsomes [6]. The CYP3A4 inhibitory IC50 sits at approximately 9 to 12 µM in vitro [6]. While CJC-1295 itself is a peptide cleared by endopeptidases rather than CYP enzymes, co-administered small molecules (for example, anastrozole or testosterone esters frequently used in the same protocol) ARE metabolized by CYP3A4. Resveratrol's inhibition of that pathway could raise plasma levels of those co-medications by 20 to 40% [7].

Sulfotransferase inhibition

Resveratrol also inhibits SULT1A1 and SULT1E1 sulfotransferases at nanomolar concentrations [8]. SULT1E1 is the primary enzyme inactivating estradiol. Inhibiting it may raise free estradiol levels modestly, which matters on protocols that include any aromatizable androgen.

The Estrogenic Activity of Resveratrol

Resveratrol binds estrogen receptor alpha (ER-alpha) and estrogen receptor beta (ER-beta) with binding affinities roughly 7,000-fold and 90-fold lower than 17-beta-estradiol, respectively [9]. At conventional supplement doses of 150 to 500 mg/day this binding is pharmacologically weak. At doses exceeding 500 mg/day, measurable changes in estrogen-responsive gene expression have been observed in breast cancer cell lines [10].

Relevance to the GH axis

GH secretion and IGF-1 sensitivity are both estrogen-modulated. Estrogens reduce hepatic GH receptor signaling, attenuating IGF-1 generation per unit of GH released [11]. In postmenopausal women, oral estradiol suppresses IGF-1 by approximately 25 to 30% compared with transdermal delivery [11]. Resveratrol's weak estrogenic activity is unlikely to reach that magnitude, but stacking it with moderate-to-high doses of CJC-1295 while also taking aromatizable androgens could create an additive estrogenic environment that blunts the intended IGF-1 rise.

Who should be most cautious

Women with hormone-receptor-positive breast cancer history, individuals on selective estrogen receptor modulators (SERMs), or men with baseline estradiol above 40 pg/mL should discuss resveratrol use with a clinician before adding it to a CJC-1295 protocol.

Pharmacokinetic Interaction: Does Resveratrol Change CJC-1295 Levels?

CJC-1295 is a peptide. It is not a substrate for CYP3A4, CYP2D6, or any hepatic microsomal enzyme. Peptide bonds are hydrolyzed by circulating dipeptidyl peptidases, endopeptidases, and renal filtration [2]. Resveratrol does not inhibit those enzymes at physiologically achievable concentrations.

The direct pharmacokinetic interaction between resveratrol and CJC-1295 is therefore negligible. Plasma levels of the peptide itself are not meaningfully altered by resveratrol co-administration.

Where the real interaction lives

The meaningful interaction is pharmacodynamic, occurring downstream at the level of the GH/IGF-1 axis, estrogen receptor signaling, and the CYP3A4-mediated metabolism of any third compound in the protocol stack. A 2021 review of GHRH analogue pharmacology in Neuroendocrinology noted that steroid hormone environment "substantially modulates somatotroph responsiveness to GHRH receptor activation," making concurrent steroid-active supplements a legitimate monitoring concern [2].

Antioxidant and Sirtuin Effects: Do They Help or Hinder GH?

Resveratrol activates SIRT1 deacetylase, which modulates mitochondrial biogenesis and insulin sensitivity [12]. SIRT1 activation may improve hepatic insulin signaling, and improved insulin sensitivity independently supports IGF-1 bioavailability because less IGF-1 is sequestered by binding proteins under insulin-sensitive conditions [13].

In a 12-week randomized controlled trial (N=75), resveratrol at 150 mg/day improved insulin sensitivity (HOMA-IR reduction of 19%) in obese adults versus placebo [14]. Better insulin sensitivity could amplify the IGF-1 response to CJC-1295. That is a plausible benefit, not a confirmed clinical outcome from a head-to-head study.

Oxidative stress and GH pulse amplitude

Some preclinical data suggest oxidative stress dampens GH pulse amplitude by impairing hypothalamic GHRH neuron firing [15]. Resveratrol's antioxidant properties might theoretically preserve pulse amplitude. No human RCT has tested this specific hypothesis with CJC-1295.

Practical Dosing and Timing

The following framework reflects standard practice at compounding-pharmacy-partnered clinics and the pharmacokinetic properties described above. It is not derived from a prospective RCT on this specific combination.

CJC-1295 non-DAC (modified GRF 1-29):

• Typical prescribed dose: 100 to 200 mcg subcutaneously, 1 to 2 times daily
• Inject 30 to 60 minutes before sleep or before a workout, on an empty stomach (food-driven insulin blunts GH pulse)
• Half-life: approximately 30 minutes; GH pulse peaks at 15 to 30 minutes post-injection

Resveratrol:

• Typical supplement dose studied: 150 to 500 mg/day orally
• Take resveratrol with a meal (fat improves absorption of trans-resveratrol)
• Separate from CJC-1295 injection by at least 2 hours to avoid any transient insulin or mTOR activation from absorption that could blunt the GH pulse

Why 2 hours? Oral resveratrol transiently activates AMPK and mTOR signaling in the intestinal wall within 60 to 90 minutes of ingestion [16]. MTOR activation from nutrient sensing is one mechanism by which postprandial states suppress GH secretion. A 2-hour buffer keeps resveratrol's absorptive phase from coinciding with the intended GH pulse window.

Monitoring Recommendations

Labs and check-in intervals for anyone combining resveratrol with CJC-1295:

| Parameter | Baseline | Week 6 | Week 12 | Ongoing | |---|---|---|---|---| | IGF-1 (serum) | Yes | Yes | Yes | Every 3 months | | Fasting glucose / HbA1c | Yes | No | Yes | Every 6 months | | Estradiol (E2) | Yes | Yes (females, high-dose resveratrol) | Yes | Every 3 months | | LH / FSH | Yes (females cycling) | No | As needed | As needed | | Liver enzymes (AST, ALT) | Yes | No | Yes | Every 6 months |

GH itself is rarely measured directly due to pulsatility; IGF-1 serves as the integrated surrogate. The Endocrine Society's 2023 Clinical Practice Guideline on Growth Hormone Deficiency recommends maintaining IGF-1 within age- and sex-adjusted reference ranges, noting that "IGF-1 values consistently above the upper limit of normal warrant dose reduction" [17].

Special Populations

Women on hormonal contraceptives or HRT

Oral contraceptives and oral estrogens already suppress hepatic IGF-1. Adding resveratrol at doses above 500 mg/day, with its SULT1E1 inhibition and weak ER agonism, may compound that suppression. The net IGF-1 response to CJC-1295 could be materially reduced. Transdermal estrogen does not suppress IGF-1 to the same degree [11], making it a preferable choice for women who want to preserve GH-axis responsiveness.

Men on testosterone replacement therapy (TRT)

Testosterone aromatizes to estradiol via CYP19A1 (aromatase). Resveratrol inhibits aromatase modestly in vitro, with an IC50 of approximately 25 µM [18]. At typical supplement doses this effect is small, but combined with an aromatase inhibitor (for example, anastrozole 0.5 mg twice weekly), resveratrol could contribute to over-suppression of estradiol. Target estradiol on TRT protocols is generally 20 to 40 pg/mL. Falling below 20 pg/mL risks libido loss, joint pain, and bone density decline [19].

Older adults (age 65+)

GH secretion declines roughly 14% per decade after age 30 [20]. Older adults prescribed CJC-1295 for confirmed GH deficiency may derive more benefit from SIRT1-activating effects of resveratrol alongside the peptide, but hepatic CYP capacity also decreases with age, raising the practical significance of any CYP3A4 inhibition on co-medications. A full medication reconciliation before starting resveratrol is especially warranted in this group.

What the Evidence Does Not Cover

No published RCT has examined the CJC-1295 plus resveratrol combination directly. The evidence base for this article is assembled from:

1. Resveratrol pharmacokinetic and enzyme-inhibition studies [4,5,6,7,8]
2. Estrogen receptor binding data for polyphenols [9,10]
3. Estrogen modulation of the GH/IGF-1 axis [11]
4. Resveratrol metabolic effects in humans [14]
5. GHRH analogue pharmacology reviews [2]
6. General peptide clearance mechanisms [2]

Absence of a direct trial means the interaction characterization here is mechanistically inferred, not empirically confirmed. Clinicians should document this limitation in informed consent discussions.

When to Avoid the Combination

Stop resveratrol and contact your prescribing clinician if you experience any of the following while on combined therapy:

• IGF-1 rising above the upper limit of your age-adjusted reference range on two consecutive draws
• New gynecomastia or breast tenderness (males)
• Menstrual irregularity not explained by other factors (females)
• Fasting glucose rising above 100 mg/dL from a previously normal baseline
• Liver enzymes (ALT or AST) exceeding 2 times the upper limit of normal